These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 12649717

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults.
    File TM, Lode H, Kurz H, Kozak R, Xie H, Berkowitz E, 600 Study Group.
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3323-31. PubMed ID: 15328092
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The efficacy and safety of amoxicillin-clavulanic acid 1000/125mg twice daily extended release (XR) tablet for the treatment of bacterial community-acquired pneumonia in adults.
    Prabhudesai PP, Jain S, Keshvani A, Kulkarni KP.
    J Indian Med Assoc; 2011 Feb; 109(2):124-7. PubMed ID: 21888181
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis.
    Sethi S, Breton J, Wynne B.
    Antimicrob Agents Chemother; 2005 Jan; 49(1):153-60. PubMed ID: 15616290
    [Abstract] [Full Text] [Related]

  • 10. Amoxicillin/clavulanate potassium extended release tablets: a new antimicrobial for the treatment of acute bacterial sinusitis and community-acquired pneumonia.
    Benninger MS.
    Expert Opin Pharmacother; 2003 Oct; 4(10):1839-46. PubMed ID: 14521493
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.
    White AR, Kaye C, Poupard J, Pypstra R, Woodnutt G, Wynne B.
    J Antimicrob Chemother; 2004 Jan; 53 Suppl 1():i3-20. PubMed ID: 14726431
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Impact of antibiotic de-escalation on clinical outcomes in community-acquired pneumococcal pneumonia.
    Viasus D, Simonetti AF, Garcia-Vidal C, Niubó J, Dorca J, Carratalà J.
    J Antimicrob Chemother; 2017 Feb; 72(2):547-553. PubMed ID: 27798219
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Efficacy and tolerability of pristinamycin vs amoxicillin-clavulanic acid combination in the treatment of acute community-acquired pneumonia in hospitalized adults].
    Poirier R, Chardon H, Beraud A, Debieuvre D, Petitprez P, Montestruc F, Lilienthal F, Janus C.
    Rev Pneumol Clin; 1997 Feb; 53(6):325-31. PubMed ID: 9616826
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Penicillin and gentamicin therapy vs amoxicillin/clavulanate in severe hypoxemic pneumonia.
    Bansal A, Singhi SC, Jayashree M.
    Indian J Pediatr; 2006 Apr; 73(4):305-9. PubMed ID: 16816491
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.